Lonitoclax

Investigational drug

Pharmaceutical compound

Lonitoclax
Clinical data

Other names	ZE50-0134
Identifiers
IUPAC name 5-[5-chloro-2-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]phenyl]-N-(4-hydroxyphenyl)-N-[(3-methoxy-2-methylphenyl)methyl]-1,2-dimethylpyrrole-3-carboxamide
CAS Number	2952589-57-8
PubChem CID	168969724
ChemSpider	133325962
UNII	76NBC3X6A3
Chemical and physical data
Formula	C₄₃H₄₅ClN₄O₅
Molar mass	733.31g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1=C(C=CC=C1OC)CN(C2=CC=C(C=C2)O)C(=O)C3=C(N(C(=C3)C4=C(C=CC(=C4)Cl)C(=O)N5CC6=CC=CC=C6C[C@H]5CN7CCOCC7)C)C
InChI InChI=InChI=1S/C43H45ClN4O5/c1-28-31(10-7-11-41(28)52-4)25-47(34-13-15-36(49)16-14-34)43(51)38-24-40(45(3)29(38)2)39-23-33(44)12-17-37(39)42(50)48-26-32-9-6-5-8-30(32)22-35(48)27-46-18-20-53-21-19-46/h5-17,23-24,35,49H,18-22,25-27H2,1-4H3/t35-/m0/s1 Key:CEWHUBSABMOQQC-DHUJRADRSA-N

Lonitoclax is an investigational new drug that is being evaluated by Lomond Therapeutics for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukaemia (CML). It acts as an Bcl-2 inhibitor.^[1]^[2]

References

↑ "Lonitoclax - Lomond Therapeutics". AdisInsight. Springer Nature Switzerland AG.
↑ Byrd J, Ledwith B, Pickersgill F, Dokukina K, Karapetian R, Sharpe C, et al. (November 2025). "A novel: Plasma apoptosis assay to demonstrate CLL cell target engagement in first-in-human study of a highly selective oral bcl-2 inhibitor lonitoclax (ZE50-0134)". Blood. 146 6819. doi:10.1182/blood-2025-6819.